Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | DDO | Q99489 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | MC3R | P41968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27884701 | 0.84 | CDK2 (0.44) | KDM4EHCAR2NAPRTCDK2ALDH1A1 | |
| SCHEMBL69399 | 0.83 | KDM4E (0.55) | KDM4EHCAR2NAPRTALDH1A1MEN1 | |
| SCHEMBL21643518 | 0.80 | CDK2 (0.41) | KDM4EHCAR2NAPRTCDK2ALDH1A1 | |
| SCHEMBL3037984 | 0.77 | TSHR (0.54) | KDM4EHCAR2NAPRTALDH1A1MEN1 | |
| SCHEMBL18038148 | 0.75 | ALDH1A1 (0.43) | KDM4ECDK2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL31118151 | 0.74 | HCAR2 (0.46) | KDM4EHCAR2NAPRTALDH1A1MEN1 | |
| SCHEMBL162262 | 0.74 | HCAR2 (0.46) | KDM4EHCAR2NAPRTALDH1A1MEN1 | |
| SCHEMBL162261 | 0.74 | HCAR2 (0.46) | KDM4EHCAR2NAPRTALDH1A1MEN1 | |
| SCHEMBL376147 | 0.73 | GRM5 (0.47) | KDM4EHCAR2NAPRTCDK2ALDH1A1 | |
| SCHEMBL14764682 | 0.73 | HCAR2 (0.45) | KDM4EHCAR2NAPRTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260145159-A1 | MIXED MODE CHARGE INDUCTION ION EXCHANGE (IEX) CHROMATOGRAPHY (MMCIIC) LIGANDS AND METHODS OF USE | BIO-RAD LABORATORIES, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20250382283-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO LTD (CN) | 2025-12-18 | — | — | US | disclosed |
| US-20240254113-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2024-08-01 | — | — | US | disclosed |
| CN-117715897-A | Compounds and their use as CD38 inhibitors | 南京艾美斐生物医药科技有限公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-4335512-A2 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HiberCell, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4330247-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | Nanjing Immunophage Biotech Co., Ltd (CN) | 2024-03-06 | — | — | EP | disclosed |
| EP-3728217-B1 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11584763-B2 | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11535635-B2 | — | — | 2022-12-27 | — | — | US | disclosed |
| WO-2022228496-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) | 2022-11-03 | — | — | WO | disclosed |
| CN-106715419-A | Aminotriazine derivatives as TANK-binding kinase inhibitor compounds | 吉利德科学公司 | 2017-05-24 | — | — | CN | disclosed |
| US-20160096827-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-04-07 | — | — | US | disclosed |
| WO-2016049211-A1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-03-31 | — | — | WO | disclosed |
| CN-102414177-B | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT | 2014-07-02 | — | — | CN | disclosed |
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| EP-2401256-B1 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT (DE) | 2013-04-17 | — | — | EP | disclosed |
| CN-102414177-A | Compounds as bradykinin b1 antagonists | BOEHRINGER INGELHEIM INT | 2012-04-11 | — | — | CN | disclosed |
| EP-2401256-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| WO-2010097372-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | KDM4E 4133/4885HCAR2 1304/4885NAPRT 3834/4885 |
| US-20260145159-A1 | MIXED MODE CHARGE INDUCTION ION EXCHANGE (IEX) CHROMATOGRAPHY (MMCIIC) LIGANDS AND METHODS OF USE | MLX, MIF, TIMCC | KDM4E 3671/4885HCAR2 2874/4885NAPRT 4430/4885 |
| US-11584763-B2 | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | PIP5K1A, PIP5K1B, PI4KA | KDM4E 1292/4885HCAR2 1694/4885NAPRT 924/4885 |
| US-11535635-B2 | — | PIP5K1A, PI4K2A, PIP5K1B | KDM4E 1488/4885HCAR2 1688/4885NAPRT 1185/4885 |
| US-20160096827-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | KDM4E 1474/4885HCAR2 3931/4885NAPRT 2422/4885 |
| US-20240254113-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | CD38, CD22, BCL6B | KDM4E 2706/4885HCAR2 980/4885NAPRT 251/4885 |
| US-20250382283-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | CD38, FCGRT, CD22 | KDM4E 1675/4885HCAR2 621/4885NAPRT 374/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | KDM4E 4133/4885HCAR2 1304/4885NAPRT 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.